White Paper
Shifting the Biomanufacturing Paradigm
![Shifting the Biomanufacturing Paradigm](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_product_file/publications/pharmaceutical-science/biopharma-reporter.com/library/shifting-the-biomanufacturing-paradigm/11409551-1-eng-GB/Shifting-the-Biomanufacturing-Paradigm.png)
The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the market to be approximately $100 billion with expectations of it growing to more than $130 billion by 2023, a robust compound annual growth rate of more than 5.5%.
The demand for mAbs and other antibody-based biologics continues to be fueled by a number of factors including:
• A growing elderly population experiencing age-related conditions including cancer, cardiovascular and respiratory diseases
• The opportunity for significant breakthroughs in cancer, diabetes, liver and kidney diseases which continue to have high mortality rates
• The availability of biosimilars and novel modalities including bispecifics and antibody-drug conjugates